KEVIN M. DE COCK, M.D., M.R.C.P., D.T.M.&H.; SUGANTHA GOVINDARAJAN, M.D.; BOONTAR VALINLUCK, B.S.; ALLAN G. REDEKER, M.D.
▸Correspondence should be addressed to Kevin M. De Cock, MD.; Special Pathogens Branch, Division of Viral Diseases, Centers for Disease Control, 1600 Clifton Road, N.E.; Atlanta, GA 30333. Reprints are not available.
DE COCK KM, GOVINDARAJAN S, VALINLUCK B, REDEKER AG. Hepatitis B Virus DNA in Fulminant Hepatitis B. Ann Intern Med. 1986;105:546-547. doi: 10.7326/0003-4819-105-4-546
Download citation file:
Published: Ann Intern Med. 1986;105(4):546-547.
Patients with fulminant hepatitis B have hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) detected for shorter periods than do patients with nonfulminant infections, and they show early and enhanced production of antibodies to HBsAg, HBeAg, and hepatitis B core antigen (HBcAg) (1-3). These observations have been interpreted as evidence that fulminant hepatitis results from the host's immunologic response to the infection rather than from hepatitis B virus replication.
Modern techniques for detecting hepatitis B virus DNA in serum provide the most sensitive method available for showing active viral replication (4-6). We examined hepatitis B virus DNA
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Viral Hepatitis, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only